Validation of the 2-ΔΔCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts

被引:426
作者
Arocho, A [1 ]
Chen, BY [1 ]
Ladanyi, M [1 ]
Pan, QL [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, Lab Diagnost Mol Pathol, New York, NY 10021 USA
关键词
chronic myelogenous leukemia; quantitative PCR; standard curve; 2(-Delta Delta Ct) calculation;
D O I
10.1097/00019606-200603000-00009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that is characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 and results in the formation of the Philadelphia (Ph1) chromosome and is present in most of CML patients. The Ph1 chromosome forms a chimeric gene that encodes an abnormal P210 mRNA transcript in most CML patients. Surveillance for minimal residual disease by detection of BCR/ABL transcripts is currently done mostly by quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR). Quantitation of BCR/ABL transcripts can monitor tumor load and the outcome of therapy. Absolute quantification determines the input copy number of the transcript of interest, usually by plotting the amount of PCR product onto a standard curve based on serial dilutions of the same product cloned in plasmids. Relative quantification describes the change in expression of the target gene in the patient sample relative to that of a control transcript by using the 2(-Delta Delta Ct) calculation. The results of real-time RT-PCR for BCR/ABL transcripts are often analyzed by using plasmid DNA standard curves. In the present study, 79 BCR/ABL transcript-positive samples from CML patients who were being monitored for minimal residual disease by real-time quantitative RT-PCR were studied to determine whether the 2(-Delta Delta Ct) approach was equivalent to the plasmid standard curve method. BCR/ABL P210 transcripts were quantitated using both the plasmid standard curve method and the 2(-Delta Delta Ct) calculation. The comparison of both methods revealed a highly significant and linear correlation between the plasmid standard curve method and the 2(-Delta Delta Ct) calculation (R-2 = 0.98, P < 0.0001). Furthermore, there was a reduction of preparation time, contamination risk, and reagent usage. The 2(-Delta Delta Ct) calculation is a convenient alternative method to derive accurate quantitative information from real time PCR assays.
引用
收藏
页码:56 / 61
页数:6
相关论文
共 21 条
[1]  
Amabile M, 2001, HAEMATOLOGICA, V86, P252
[2]   Chronic myeloid leukemia - A minimalistic view of post-therapeutic monitoring [J].
Bagg, A .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2002, 4 (01) :1-10
[3]   Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase [J].
Branford, S ;
Rudzki, Z ;
Harper, A ;
Grigg, A ;
Taylor, K ;
Durrant, S ;
Arthur, C ;
Browett, P ;
Schwarer, AP ;
Ma, D ;
Seymour, JF ;
Bradstock, K ;
Joske, D ;
Lynch, K ;
Gathmann, I ;
Hughes, TP .
LEUKEMIA, 2003, 17 (12) :2401-2409
[4]   Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems [J].
Bustin, SA .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2002, 29 (01) :23-39
[5]   The molecular biology of chronic myeloid leukemia [J].
Deininger, MWN ;
Goldman, JM ;
Melo, JV .
BLOOD, 2000, 96 (10) :3343-3356
[6]   Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia [J].
Drunat, S ;
Olivi, M ;
Brunie, G ;
Grandchamp, B ;
Vilmer, E ;
Bièche, I ;
Cavé, H .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) :281-289
[7]   Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program [J].
Gabert, J ;
Beillard, E ;
van der Velden, VHJ ;
Bi, W ;
Grimwade, D ;
Pallisgaard, N ;
Barbany, G ;
Cazzaniga, G ;
Cayuela, JM ;
Cavé, H ;
Pane, F ;
Aerts, JLE ;
De Micheli, D ;
Thirion, X ;
Pradel, V ;
González, M ;
Viehmann, S ;
Malec, M ;
Saglio, G ;
van Dongen, JJM .
LEUKEMIA, 2003, 17 (12) :2318-2357
[8]   Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients [J].
Guo, JQ ;
Lin, H ;
Kantarjian, H ;
Talpaz, M ;
Champlin, R ;
Andreeff, M ;
Glassman, A ;
Arlinghaus, RB .
LEUKEMIA, 2002, 16 (12) :2447-2453
[9]   Molecular monitoring of chronic myeloid leukemia [J].
Hughes, T ;
Branford, S .
SEMINARS IN HEMATOLOGY, 2003, 40 (02) :62-68
[10]   Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use [J].
Jones, CD ;
Yeung, C ;
Zehnder, JL .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (01) :42-48